ALG-000184 Drug Interaction Study in Healthy Volunteers
What You Need to Know Before You Apply
What is the purpose of this trial?
This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs).In Part 1, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Itraconazole; participants will be assigned to receive multiple doses of ALG-000184 and Itraconazole over a two week period.In Part 2, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Carbamazepine; participants will be assigned to receive multiple doses of ALG-000184 and ascending doses of Carbamazepine over an 18 day period.The 2 parts may be conducted in parallel.
Do I have to stop taking my current medications for this trial?
The trial does not specify if you need to stop taking your current medications. However, since it involves drug interactions, you might need to discuss your current medications with the study team.
Are You a Good Fit for This Trial?
This clinical trial is for healthy individuals who want to help test how the new drug ALG-000184 interacts with other drugs. Participants will take multiple doses of ALG-000184 along with either Itraconazole or Carbamazepine over a period of two weeks to eighteen days.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part 1
Participants receive multiple doses of ALG-000184 and Itraconazole over a two week period to evaluate drug-drug interaction potential
Treatment Part 2
Participants receive multiple doses of ALG-000184 and ascending doses of Carbamazepine over an 18 day period to evaluate drug-drug interaction potential
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ALG-000184
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aligos Therapeutics
Lead Sponsor